PDSB - PDS Biotechnology Corp
IEX Last Trade
1.64
-0.005 -0.305%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:22 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$1.64
-0.01
-0.30%
Fundamental analysis
21%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
15%
Performance
5 Days
-0.61%
1 Month
-24.42%
3 Months
-45.87%
6 Months
-48.10%
1 Year
-69.23%
2 Year
-83.21%
Key data
Stock price
$1.64
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.69 - $6.68
52 WEEK CHANGE
-$67.72
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Frank K. Bedu-Addo
Region: US
Website: pdsbiotech.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pdsbiotech.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.
Recent news